Verve Therapeutics, Inc.: insider trades · United States · SEC (Form 4)

About Verve Therapeutics, Inc.

Verve Therapeutics, Inc. is a U.S.-based biotechnology company listed on the Nasdaq stock market in the United States under the ticker VERV. The company was founded in 2018 in Boston by pioneers in cardiology, gene editing, and drug development, with a focused mission: to change the treatment paradigm for atherosclerotic cardiovascular disease by developing one-time, in vivo gene-editing medicines rather than chronic therapies. Its headquarters are in Boston, placing it at the center of the U.S. biotech ecosystem. Verve’s business model is built around a genetic-medicine platform aimed at validated cardiovascular targets. Its lead program, VERVE-102, targets PCSK9, a well-established driver of LDL cholesterol biology and cardiovascular risk. The program is designed to deliver durable reductions in LDL-C, with potential applications in heterozygous familial hypercholesterolemia and selected patients with premature coronary artery disease. Beyond VERVE-102, the company has also been building a broader pipeline of preclinical and clinical assets focused on pathways linked to cardiovascular risk, which gives it strategic optionality beyond a single product candidate. From a competitive standpoint, Verve occupies a specialized but potentially high-value niche in next-generation cardiometabolic medicine. Its differentiation lies in the ambition to offer a treatment that may be administered once, or very infrequently, in a therapeutic area historically dominated by lifelong chronic medication. That proposition is compelling because adherence remains a major challenge in lipid management and secondary prevention, and a durable gene-editing approach could expand the addressable market if long-term safety and efficacy continue to hold up. Recent clinical and corporate developments have been material. In 2025, Verve reported encouraging early data for VERVE-102, including a favorable safety profile and dose-dependent reductions in LDL-C and PCSK9 protein. More importantly from a capital-markets perspective, Verve announced in June 2025 a definitive agreement to be acquired by Eli Lilly, and that transaction was completed in July 2025. For investors, this sequence underscored both the strategic value of the platform and the interest of a large pharmaceutical partner in cardiovascular gene editing. Geographically, Verve is primarily a U.S. company in terms of headquarters, listing, and corporate governance, while its clinical development has included trial activity across multiple countries. Overall, Verve represents a high-science, high-risk biotechnology story in cardiovascular medicine, with recent M&A activity materially changing its public-market profile on Nasdaq in the United States.